neoadjuvant chemotherapy triple negative breast cancer

Release time ：Dec-24,2024

Neoadjuvant chemotherapy is a frequently utilized approach in the treatment of triple-negative breast cancer, typically administered prior to surgery to diminish the size of the tumor and enhance the likelihood of a successful surgical outcome. While this therapeutic modality may induce certain side effects in patients, its overarching goal is to achieve better disease management.

The side effects associated with neoadjuvant chemotherapy can vary in severity, ranging from mild to severe. Common manifestations include nausea, vomiting, alopecia, and fatigue, which generally subside following the conclusion of treatment. Less frequently observed side effects encompass cardiac damage, pulmonary infections, and blood clots, which may necessitate additional medical intervention. Fortunately, in the majority of instances, these can be managed with prompt diagnosis and treatment.

For individuals receiving neoadjuvant chemotherapy for triple-negative breast cancer, vigilant self-monitoring of their health status is essential, and they should seek immediate medical attention for any abnormal symptoms that arise. Moreover, adherence to the physician's recommendations, punctual treatment, and maintenance of proper nutrition and rest during the treatment period are paramount. It is imperative to remember that each person's response to therapy is unique, thus close collaboration with your healthcare team to comprehend your individual circumstances and requirements is vital.